CONTACT

Contact Us

Suite 1-2
Willow House
Strathclyde Business Park
Kestrel View
Bellshill ML4 3PB

Tel: +44 (0)169 846 4224
Email: enquiries@mgb-biopharma.com

News

MGB Biopharma Announces Successful End-of-Phase 2 Meeting with FDA for MGB-BP-3, a Potential New Gold Standard, First-Line Treatment for Clostridioides difficile Infection (CDI)

MGB Biopharma Announces Successful Outcome from Phase II Clinical Study with MGB-BP-3 – a Potential New Gold Standard, First-Line Treatment for Clostridium difficile Infection (CDI)

MGB Biopharma Presents at INV€$TIVAL SHOWCASE 2019

Bio-Europe 2019

MGB Biopharma to Attend Upcoming BioEurope Meeting in Hamburg on 11 to 13 Nov 2019

MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3

Join our mailing list

Menu